OR502 + CEMIPLIMAB for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Oct 2023: Trial registered, NCT06090266
  2. 24 Oct 2023: Trial started, NCT06090266

The trials

NCT06090266: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

State
Under way
Phase
Phase 1 and Phase 2
People
168 planned
Started
24 Oct 2023
Primary completion
1 Aug 2026
Arms
OR502 monotherapy and combination therapy dose-escalation phase (Part A), OR502 monotherapy and combination therapy dose-expansion phase (Part B)
Results
None posted
  1. 19 Oct 2023: Trial registered
  2. 24 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.